Table 3.
HRs (95% CIs) of CHD according to different levels of BMI at baseline among various subpopulationsa
| BMI (kg/m2) |
P for trend | P for interaction | |||||
|---|---|---|---|---|---|---|---|
| <25.0 | 25.0–29.9 | 30–34.9 | 35–39.9 | ≥40 | |||
| Men | |||||||
| Age groups (years) | >0.50 | ||||||
| <50 | 1.00 | 1.07 (0.86–1.33) | 1.19 (0.96–1.48) | 1.47 (1.19–1.85) | 1.44 (1.15–1.80) | <0.001 | |
| 50–59 | 1.00 | 1.28 (1.01–1.60) | 1.48 (1.17–0.85) | 1.57 (1.23–2.00) | 1.56 (1.22–2.01) | <0.001 | |
| ≥60 | 1.00 | 1.01 (0.8–1.27) | 1.07 (0.84–1.35) | 1.42 (1.10–1.85) | 0.83 (0.59–1.15) | 0.38 | |
| Race | >0.10 | ||||||
| African American | 1.00 | 1.18 (0.99–1.40) | 1.26 (1.05–1.51) | 1.54 (1.26–1.88) | 1.53 (1.24–1.89) | <0.001 | |
| White | 1.00 | 1.08 (0.89–1.32) | 1.27 (1.05–1.54) | 1.54 (1.26–1.88) | 1.35 (1.10–1.66) | <0.001 | |
| Smoking status | <0.05 | ||||||
| Never | 1.00 | 1.17 (0.95–1.44) | 1.35 (1.10–1.67) | 1.68 (1.35–2.09) | 1.70 (1.36–2.12) | <0.001 | |
| Ever or current | 1.00 | 1.33 (1.09–1.62) | 1.41 (1.15–1.73) | 1.61 (1.28–2.03) | 1.38 (1.08–1.76) | <0.001 | |
| Glucose-lowering medication | >0.25 | ||||||
| No use | 1.00 | 1.56 (1.19–2.06) | 1.40 (1.05–1.88) | 1.66 (1.20–2.29) | 1.85 (1.33–2.56) | 0.001 | |
| Oral hypoglycemic agents | 1.00 | 1.25 (0.95–1.65) | 1.46 (1.11–1.92) | 1.66 (1.23–2.23) | 1.57 (1.15–2.14) | <0.001 | |
| Metformin | 1.00 | 1.08 (0.87–1.34) | 1.31 (1.06–1.62) | 1.56 (1.24–1.95) | 1.47 (1.16–1.85) | <0.001 | |
| Sulfonylureas | 1.00 | 1.04 (0.83–1.32) | 1.24 (0.98–1.56) | 1.47 (1.15–1.88) | 1.32 (1.02–1.71) | <0.001 | |
| Other oral agents | 1.00 | 1.13 (0.78–1.66) | 1.35 (0.93–1.95) | 1.52 (1.03–2.22) | 1.76 (1.20–2.59) | <0.001 | |
| Insulin | 1.00 | 1.09 (0.88–1.34) | 1.29 (1.05–1.58) | 1.56 (1.26–1.94) | 1.49 (1.19–1.86) | <0.001 | |
| Women | |||||||
| Age groups (years) | >0.05 | ||||||
| <50 | 1.00 | 1.10 (0.89–1.37) | 1.04 (0.84–1.29) | 1.09 (0.88–1.35) | 1.06 (0.86–1.30) | 0.70 | |
| 50–59 | 1.00 | 0.89 (0.73–1.08) | 0.88 (0.73–1.07) | 1.02 (0.84–1.24) | 1.06 (0.87–1.28) | 0.048 | |
| ≥60 | 1.00 | 0.89 (0.72–1.09) | 0.89 (0.73–1.09) | 0.99 (0.79–1.23) | 1.06 (0.85–1.33) | 0.46 | |
| Race | >0.20 | ||||||
| African American | 1.00 | 0.90 (0.77–1.05) | 0.85 (0.72–0.99) | 1.06 (0.90–1.24) | 1.07 (0.92–1.26) | 0.005 | |
| White | 1.00 | 1.03 (0.86–1.23) | 1.09 (0.91–1.30) | 1.08 (0.90–1.29) | 1.13 (0.95–1.35) | 0.17 | |
| Smoking status | >0.75 | ||||||
| Never | 1.00 | 0.92 (0.77–1.08) | 0.96 (0.82–1.13) | 1.06 (0.90–1.26) | 1.11 (0.94–1.31) | 0.005 | |
| Ever or current | 1.00 | 1.05 (0.85–1.29) | 1.04 (0.85–1.28) | 1.11 (0.89–1.37) | 1.10 (0.89–1.37) | 0.21 | |
| Glucose-lowering medication | >0.05 | ||||||
| No use | 1.00 | 1.05 (0.82–1.34) | 1.08 (0.84–1.38) | 1.08 (0.83–1.40) | 1.30 (1.01–1.67) | 0.029 | |
| Oral hypoglycemic agents | 1.00 | 0.94 (0.75–1.17) | 0.87 (0.70–1.08) | 0.93 (0.74–1.16) | 0.89 (0.71–1.12) | 0.43 | |
| Metformin | 1.00 | 1.04 (0.86–1.26) | 1.04 (0.86–1.26) | 1.16 (0.95–1.40) | 1.12 (0.93–1.36) | 0.073 | |
| Sulfonylureas | 1.00 | 0.85 (0.69–1.05) | 0.92 (0.75–1.12) | 0.99 (0.80–1.22) | 0.99 (0.81–1.22) | 0.17 | |
| Other oral agents | 1.00 | 0.79 (0.60–1.03) | 0.77 (0.59–0.99) | 0.83 (0.64–1.09) | 0.83 (0.64–1.07) | 0.80 | |
| Insulin | 1.00 | 0.90 (0.74–1.10) | 0.97 (0.80–1.18) | 1.12 (0.92–1.36) | 1.14 (0.94–1.38) | 0.001 | |
aAdjusted for age, race, types of insurance, income, and smoking, other than the variable for stratification.